LB-100

立即咨询

LB-100

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1026680-07-8

包装与价格：

包装	价格(元)
5mg	询价
25mg	询价
100mg	询价

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	268.31
Cas No.	1026680-07-8
Formula	C₁₃H₂₀N₂O₄
Solubility	≥26.8 mg/mL in H2O; insoluble in EtOH; insoluble in DMSO
Chemical Name	3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
Canonical SMILES	CN1CCN(C(C(C2CCC3O2)C3C(O)=O)=O)CC1
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

LB-100 is an inhibitor of protein phosphatase 2A (PP2A) with anticancer activity, with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells, respectively[1].

In BxPc-3, Panc-1, and SW1990 cells, LB-100 treatment reduced PP2A activity by 30-50%. LB-100 increases the intracellular doxorubicin concentration (about 2.5 times that of the control group) and makes tumor cells more sensitive to the cytotoxicity of doxorubicin[1].

In a PANC-1 mouse xenograft model, LB-100 (2 mg / kg, intraperitoneal injection) improves the efficacy of the chemotherapy drug doxorubicin. LB-100 increases tumor microvessel density and blood flow velocity on the tumor surface, and decreases tumor volume[1].

Reference:

[1]. Bai X, Zhi X, Zhang Q, et al. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Lett, 2014, 355(2): 281-287.

试验操作

Cell experiment:[1]
Cell lines	Pancreatic cancer cell lines BxPc-3 and Panc-1
Reaction Conditions	0.85 and 3.87 μM LB-100
Applications	LB-100 showed dose-dependent inhibition of cell growth in both cell lines. The IC50 of LB-100 was 0.85 μM and 3.87 μM in BxPc-3 and Panc-1, respectively. While the IC50 of doxorubicin was 2.3 μM and 1.7 μM in BxPc-3 and Panc-1, respectively, LB-100 did not synergize with doxorubicin in both cell lines.
Animal experiment:[1]
Animal models	BALB/c nude mice bearing Panc-1 xenografts
Dosage form	2 mg/kg Injected intraperitoneally (i.p.) on alternate days for a total of 16 days
Applications	LB-100 synergistically enhanced the activity of doxorubicinin vivo. This effect was associated with increased microvessel density, blood perfusion, and doxorubicin concentrations within the xenografts.
Note	The technical data provided above is for reference only.
	References: 1. Bai X, Zhi X, Zhang Q, et al. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Letters, 2014, 355(2): 281-287.